Oruka Therapeutics, Inc.
ORKA
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.5B
Close$
$0.99
98.9% downside
Current Fair Value
98.9% downsideOvervalued by 98.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.50 Billion |
|---|---|
| Enterprise Value | $5.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.31 |
| Beta | -0.39 |
| Outstanding Shares | 62,872,318 |
Return
| Return on Equity | -11.92% |
|---|---|
| Return on Assets | -11.66% |
| Return on Invested Capital | -13.89% |
Valuation & Multiples
| P/E Ratio | -36.9 |
|---|---|
| PEG | -54.52 |
| Price to Sales | - |
| Price to Book Ratio | 5.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -33.73 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7845▼ 134.43% |
|---|---|
| Total Calls | 187,900▲ 365.10% |
| Total Puts | 147,400▲ 71.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 141.30%▲ 47.02% |
|---|---|
| Total Invested | $7.12B▲ 179.32% |
| Investors Holding | 266▲ 79.00% |
ESG Score
No data
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.